Metastatic CRPC: Novel Treatment Strategies With Radioligand Therapy
Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.
Read More
Radioligands in the Treatment of Metastatic CRPC: Radium-223
Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.
Read More
Radioligands in the Treatment of Metastatic CRPC: Lutetium-177–PSMA-617
Focused discussion on the role of lutetium-177–PSMA-617 as radioligand therapy in patients with metastatic castration-resistant prostate cancer.
Read More
Combination PARPi Strategies in Metastatic CRPC: Interpreting Data From Clinical Trials
Key opinion leaders in metastatic castration-resistant prostate cancer management review a subset of clinical trials focused on combination strategies with PARP inhibitors.
Read More
Advent of PARP Inhibitors in Metastatic CRPC
Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.
Read More
Evolving Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer
Comprehensive insight to key treatment modalities for patients with nonmetastatic castration-resistant prostate cancer and how to select amongst them.
Read More
Informing Systemic Therapy Selection With Negative Data in HSPC
A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.
Read More
What is the Role of Locoregional Therapy in Metastatic HSPC?
Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.
Read More
Final Thoughts on the Management of mRCC
Read More
Additional Emerging Therapies for Progressive mRCC
Read More
Emerging Agents for Progressive mRCC
Read More
Sequencing After Frontline I/O Based Regimen for mRCC
Read More
Clinical Trials for Relapsed/Refractory mRCC
Read More
Upcoming Combination Trials for mRCC
Read More
I/O Therapy After Progression on I/O for mRCC
Read More
Role of TKI After Progression on I/O for mRCC
Read More
Review of the COSMIC 021 Study for mRCC
Read More
Introduction and Review of CheckMate 9ER for Metastatic RCC
Read More